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oligodendrocytes. This study contributes to the elucida-
tion of effects of KYNA on oligodendrocytes in vitro, yet 
further analyses are necessary to explain the mechanisms 
behind the damage and loss of myelin sheaths.
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Introduction
Kynurenine pathway (KP) serves as the main route of trypto-
phan metabolism resulting in nicotinamide adenine dinucle-
otide (NAD+) as well as so-called kynurenines formation. 
Thus far, it has been well established that kynurenines exert 
key biological functions in the mammalian central nervous 
system (CNS) being able to affect the activity of several glu-
tamate receptors. Remarkable changes in the ratio between 
tryptophan and its metabolites are often the hallmark of a 
variety neurological disorders i.e. Huntington’s disease, 
Alzheimer’s disease, Parkinson’s disease, seizure disorders, 
dementia, schizophrenia, and depression [1, 2].
Kynurenic acid (KYNA) is one of the catabolic end stage 
products of KP and its’ neuroprotective role in the brain is 
well recognized. This endogenous tryptophan metabolite is 
usually found in the brain at nanomolar concentrations and is 
known to exert anticonvulsant and sedative activities [1, 3].
Although the effects of KYNA on neural cells, both 
under physiological and pathological conditions have been 
excessively studied [2], its’ effect on oligodendroglial cells 
and on th  myelin sheath is poorly understood. The recent 
study by Dabrowski and colleagues shows myelin damage 
and loss in the spinal cord of rats continuously infused with 
high doses of KYNA [4]. Importantly, the loss of myelin 
Abstract Kynurenic acid (KYNA) is an end stage prod-
uct of tryptophan metabolism with a variety of functions in 
the human body, both in the cen ral nervous system (CNS) 
and in other organs. Although its activity in the human 
brain has been widely studied and effects on neural cells 
were emphasized, the effect of KYNAon oligodendroglial 
cells remains unknown. Present study aims at descri ng 
the activity of high concentration of KYNA in OLN-93 
cells. The inhibition of OLN-93 oligodendrocytes viability 
by KYNA in a medium with reduced serum concentra-
tion has been demonstrated. Al hough decreased metabolic 
activity of KYNA treated OLN-93 cells was shown, the 
cells proliferation was not altered. KYNA treatment did 
not alter morphology as well as xpression level of cell 
cycle and proliferation regulating proteins. Furthermore, 
glutamate receptor antagonist  and agonists did not alter 
the inhibitory effect of KYNA on viability of OLN-93 
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Cell Viability Assessment––MTT Assay
Cells viability was determined with use of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay. Cells were seeded onto 96-well microplates at 
a density of 1 × 104 cells/well. The next day, the medium was 
replaced with the fresh one with reduced FBS to a concen-
tration of 2 % (c ntrol) or with indicated concentrations of 
KYNA, glutamate antagonists (CPPene, MK-801 and GYKI 
52466) and glutamate agonists (glutamate, NMDA, AMPA 
and ATPA). After 24 h of incubation, MTT solution (5 mg/
ml) was added (final concentration of 0.75 mg/ml) and incu-
bated for 3 h. Resultant formazan crystals were solubilized 
overnight in sodium dodecyl sulfate (SDS, Sigma Aldrich) 
buffer (SDS in 0.01 N HCl). Absorbance was recorded on a 
microplate reader (BioTek ELx800, Winooski, VT, USA) at 
the wavelength of 570 nm.
Cell Proliferation Assessment––MTT Assay
Cells were seeded onto 96-well microplates at a density of 
2.5 × 103 cells/well. The next day, the medium was replaced 
with the fresh one alone (control) or with indicated concen-
trations of KYNA (10, 50, 100, 250, 500, 1000 µM). After 
48 or 96 h of incubation, MTT solution (5 mg/ml) was added 
(final concentration of 0.75 mg/ml) and incubated for 3 h. 
Resultant formazan crystals were solubilized overnight in 
sodium dodecyl sulfate (SDS, Sigma Aldrich) buffer (SDS 
in 0.01 N HCl). Absorbance was recorded on a microplate 
reader (BioTek ELx800, Winooski, VT, USA) at the wave-
length of 570 nm.
Cell Proliferation Assessment––BrdU Assay
Cells were seeded onto 96-well microplates at a density of 
2.5 × 103 cells/well. The next day, the medium was replaced 
with the fresh one alone (control) or with indicated concen-
trations of KYNA (1, 5, 10, 25, 50, 100, 250, 500, 1000 µM). 
After 48 h of incubation, BrdU was added and the follow-
ing steps were performed according to the manufacturer’s 
procedures (Cell Proliferation ELISA BrdU, Roche Diag-
nostics GmbH, Penzberg, Germany). Absorbance was mea-
sured at a wavelength of 450 nm using microplate reader 
(BioTek ELx800).
Cell Morphology/Cytoskeleton Visualization
The morphology of oligodendroglial cells treated with 
KYNA was shown by F-actin filament staining with use of 
rhodamine-conjugated phalloidin (RHPH). Cells grown on 
chamber slides (Nunc) coated with poly-d-lysine (50 µg/
ml) were subjected to 500 μM KYNA (in a medium with 
reduced concentration of FBS to 2 %) for 24 h. Then, he 
was not associated with inflammatory infiltration, death 
of oligodendrocytes or damage to naked axons indicating 
a specific but yet unknown effect of KYNA on oligoden-
drocytes. The present study aims to evaluate the influence 
of KYNA on OLN-93 oligodendroglial cells in vitro and 




If not indicated otherwise, chem cals use  in the study 
were purchased from Sigma–Aldrich Co. (St. L uis, 
MO, USA). CPPene ((R)-4-[(E)-3-phosphonop -
2-enyl]piperazine-2-carboxylic cid) was btained from 
Sandoz (Basel, Switzerland). AMPA ((S)-α-Amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) and ATPA 
((RS)-2-Amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)
propanoic acid) were purchased f om Tocris Bi sci-
ence (Bristol, UK). All chemicals except KYNA, AMPA, 
ATPA and GYKI 52466 were dissolved in phosphate buff-
ered saline (PBS) to prepare stock solutions as follow: glu-
tamate 0.5 M, NMDA 50 mM, CPPene 25 mM, MK-801 
10 mM. KYNA 0.5 M was dissolved in 1 N NaOH fol-
lowed by PBS addition (final concentration of NaOH in 
stock solution and culture medium did not exceed 68 and 
0.136 %, respectively). AMPA was d ssolved in 1 N HCl 
followed by PBS addition (final concentration of HCl in 
stock solution and culture medium did not exceed 20 and 
0.04 %, respectively). GYKI 52466 was dissolved in 5N 
HCl followed by PBS addition (final concentration of HCl 
in stock solution and culture medium did not exceed 2 
and 0.02 %, respectively). ATPA 150 mM was dissolved in 
DMSO followed by addition of PBS (final concentration 
of DMSO in stock solution and cul ure m dium did not 
exceed 50 and 0.067 %, respectively). Wo king solutions
were prepared each time in fres culture medium. In addi-
tion, the maximal concentration of the solvent was tested 
in cultures and no changes in cell growth and morphology 
were observed.
Cell Culture
Oligodendrocyte cell line OLN-93 was obtained from 
Department of Neonatolgy, Charité-Virchow Clinics, 
Humboldt University, Berlin, G r any and maintained 
in DMEM/F12 HAM (1:1) (Dulbecco’s Modified Eagle’s 
Medium/Nutrient mixture F-12 HAM) in a humidified 
atmosphere of 95 % air and 5% CO2 at 37°C. Culture 
medium was supplemented with 10 % fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (100 μg/ml).
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Results
Effect of KYNA on Viability of OLN-93 Cells In Vitro
In the first set of experiments evaluation of OLN-93 cells 
viability was performed upon KYNA treatment. Cells were 
exposed to sequential dilutions of KYNA for 24h in a 
medium containing 2 % FBS a d MTT test was performed. 
Decreased viability of cells was observed upon treat-
ment with KYNA in a concentration range: 250–1000 µM 
(Fig. 1). The highest concentration tested decreased cell 
viability over 40 % vs control conditions.
Effect of KYNA on Proliferation and Morphology of 
OLN-93 Cells In Vitro
In order to assess the impact of KYNA on oligodendrog-
lial cells’ growth/proliferation, MTT test was used upon 48 
and 96 h of incubation with tested compound in a medium 
containing 10 % FBS. No statistically significant effect on 
OLN-93 cells proliferation has been shown (Fig. 2a). Simi-
larly, BrdU incorporation-based test has shown no altera-
tion in DNA synthesis within OLN-93 cells in vitro after 
48 h incubation with 1–1000 µM concentrations of KYNA 
(Fig. 2b).
To further explore the influence of KYNA on the cell 
morphology, actin filaments were visualized with RHPH. 
No changes in cytoskeleton composition and morphology 
of OLN-93 cells upon KYNA 500 µM treatment were noted 
(Fig. 3a). Moreover, no cell death induction, neither apop-
tosis nor necrosis, was observed due to KYNA treatment 
(data not shown).
cells were rinsed twice with PBS and fixed with 3.7 % para-
formaldehyde for 20 min, followed by 5 min permeabili-
zation in 0.1 % Triton X− 00. Next, half-hour incubation
with phalloidin-rhodamine (66 pmol/ml) was performed. 
Nuclei were counterstained for 5 min wi h Hoechst 33342 
(0.24 μg/mL). Cell images were captured with fluorescence 
microscopy (Olympus BX51 System Microscope; Olympus 
Optical Co., Ltd., Tokyo, Japan, and CellFamily A alySIS 
software) at ×400 magnification.
Assessment of Cell Death–Cell Death Detection ELISA
Cells were seeded onto 96-well microplates at a density of 
1 × 104 cells/well. The next day, th  medium was replaced 
with the fresh one alone (control) or with 500 μM KYNA 
for 24 h. Next, the following steps were performed accord-
ing to the manufacturer’s proce u es of Cell Death Detec-
tion ELISAPLUS kit (Roche Diagnost cs). Absorbance was 
measured at 405 nm wavelength using microplate reader 
(BioTek ELx800).
Immunobloting
For western blot analysis 500 µM KYNA (in a medium with 
reduced to a concentration of 2 % FBS) was used. OLN-93 
cells after treatment were wash d wi h ic -cold PBS, har-
vested with 5 mM EDTA and lysed for 1 h in ice-cold l s s 
buffer consisting of 1 % NP40, 0.5 % sodium deoxycholate, 
0.1 % SDS, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO 4, 
20 mM NaF, 0.5 mM DTT, 1mM PMSF and protease
inhibitor cocktail in PBS pH 7.4. After cent ifugation in 
4 °C (14,000×g for 10 min) supernatants were collected and 
solubilized in 6× La mmli sample buffer (0.5 M Tris/HCl 
pH 6.8, 30 % glycerol, 10 % SDS, 5 % β-merkaptoetanol, 
0.012 % bromophenol blue). Forty micrograms of total pro-
tein were separated by SDS–PAGE (10–14 % SDS–poly-
acrylamide gel) and then transferred into PVDF membrane 
(Millipore, Billerica, MA, USA). The blots were probed 
overnight with indicated primary antibodies phospho-
ERK1/2 (Thr202/Tyr204, 1:1000), phospho-Akt (Ser473, 
1:1000), cyclin D1 (1:2000), CDK4 (1:1000), CDK6 
(1:1000) and β-actin (1:1000) from Cell Signaling Technol-
ogy, Beverly, MA, USA and p21 (1:1000) from Santa Cruz 
Biotechnology, Dallas, TX, USA. Primary antibodies were 
then detected with HRP-conjugated secondary antibodies 
(1:2000; Cell Signaling Technology). The visualization of 
the proteins was performed using an enhanced chemilumi-
nescence detection system (Pierce, Rockford, IL, USA).
Statistical Analysis
The data were plotted as the mean ± SD with use GraphPad 
Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Fig. 1 Effect of KYNA on viability of OLN-93 cells in vitro. OLN-93 
cells were exposed to indicated concentrations of KYNA (in a medium 
with reduced to 2 % FBS) and viability was measured after 24 h by 
MTT test. The values were means ± SD; n=  6. *At least p < 0.05 vs. 
control (one-way ANOVA test, post test: Tukey), C control
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Effect of Glutamate Receptor Antagonists on Activity of 
KYNA on OLN-93 Cells In Vitro
Glutamate receptor antagonists including CPPene (25, 
50 µM), MK-801 (50, 100 µM) and GYKI 52466 (50, 
100 µM) were used alone or in combination with KYNA 
(500 µM) and viability of treated oligodendroglial cells was 
assessed after 24 h wi h MTT test. All of tested antagonists 
did not stop the effect of KYNA that decreased viability of 
OLN-93 cells (Fig. 4a–c). Moreover, CPPene did not induce 
changes in cells’ viability when applied separately (Fig. 4a). 
In order to evaluate whether KYNA affects expression 
of proteins regulating cells’ proliferation and cell cycle, 
western blot analyses were performed. No significant 
changes in phosphorylation level of extracellular-signal 
regulated kinases 1/2 (ERK1/2) on Thr202Tyr204 and 
protein kinase B (Akt) on Ser473 were noted (Fig. 3b left 
panel). No meaningful changes in express on of bo h cell 
cycle stimulators i.e. cyclin D1, cycl n-dependent kinases 
CDK4, CDK6 and cell cycle inhibitor p21 protein were 
detected upon KYNA 500 µM incubation (Fig. 3b right 
panel).
Fig. 3 Effect of KYNA on OLN-93 cell morphology and expression 
of proteins regulating proliferation and cell cycle. a OLN-93 c lls 
after 24 h exposure to medium alone (control) or KYNA 500 µM were 
fixed and stained with rhodamine-conjugated phalloidin (red); nuclei 
were counterstained with Hoechst 33342 (blue). Images were cap-
tured at ×400 magnification. b OLN-93 cells were incubated for 24 h 
with medium alone (C trol) or KYNA 500 µM, harvested and lysed. 
40 µg of total protein was separated by SDS–PAGE, transferred on 
PVDF membranes and expression of p-ERK1/2 (Thr202/Tyr204), p-Akt 
(Ser473), cyclin D1, CDK4, CDK6 and p21 proteins was visualized by 
w stern blot analyses. β-actin was used as an internal control
 
Fig. 2 Effect of KYNA on proliferation of OLN-93 cells in vitro. a 
OLN-93 cells were exposed to indicated concentrations of KYNA (in a 
medium with 10 % FBS) for 48 or 96 h and proliferation was measured 
by MTT test. The data were means ± SD; n = 6 and were analyzed by 
means of linear regression. b OLN-93 cells were exposed to indicated 
c ncentrations of KYNA (in a medium with 10% FBS) for 48 h and 
proliferation was assessed by BrdU test. The values were means ±SD; 
n =  18. *At least p < 0.05 vs. control (one-way ANOVA test, post test: 
Tukey), C control
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of KYNA with no apparent death of oligodendrocytes [4]. 
Therefore, in the present study we have performed a series 
of experiments aiming to elucidate the mechanism of KYNA 
activity on oligodendrocytes in vitro.
A permanent OLN-93 cell line obtained from spontane-
ously transformed cells in primary cultures of rat brain [6] 
was used in the study. The cells were shown to resemble 
the features of primary oligodendrocytes with the abil-
ity to differentiate into late immature oligodendrocytes, 
depending on serum concentration in the growth medium 
[6, 7]. Furthermore, previous study of our group demon-
strated kynurenine aminotransferases I and II (KAT I and 
KAT II) expression in OLN-93 cells as well as the ability 
of these cells to synthesize KYNA from exogenously added 
l-kynurenine [8]. Here, we have explored the influence of 
exogenously added KYNA on OLN-93 cells viability and 
proliferation. A reduction in cell viability has been noted in 
cultures incubated with increasing concentrations of KYNA. 
Concomitantly, no changes in cell proliferation have been 
indicated which had been screened both by metabolic activ-
ity and BrdU incorporation assessment. Discrepancy in the 
observed metabolic activity of cells when tested for cell via-
bility and cell proliferation may be linked to different serum 
concentration in the incubation medium, reduced (2 %) or 
standard (10 %), respectively. According to several studies 
describing intracellular modifications in OLN-93 cells in 
low-serum and serum-deprivation conditions [6, 7, 9] we 
cannot exclude the influence of various culture conditions 
on our study results. However, taking into consideration 
described measurements as well as microscopic obser-
vations of KYNA treated OLN-93 cells, we may clearly 
conclude that KYNA (1–1000 µM) does not affect OLN-
93 cells proliferation, DNA synthesis and morphology, 
yet in concentration range 250–1000 µM it downregulates 
Viability of cells treated with MK-801 and GYKI 52466 was 
slightly changed, however, the influence of applied antago-
nists was opposite. MK-801 in concentration of 100 µM 
increased cell viability by 7.4 % (Fig. 4b). GYKI 52466 at 
50 and 100 µM decreased cell viability by 7.9 and 11.4 %, 
respectively (Fig. 4c).
Effect of Glutamate Receptor Agonists on KYNA 
Activity in OLN-93 Cells In Vitro
Glutamate receptor agonists including glutamate (500, 
1000 µM), NMDA (100, 200 µM) and AMPA (50, 100 µM) 
were used alone or in combination with KYNA (500 µM) 
for 24 h and the viability of trea ed oligodendroglial cells 
was assessed with the MTT test. All tested agonists applied 
alone did not affect the viability of OLN-93 cells in vitro 
(Fig. 5a, b) with except for AMPA at 100 µM and ATPA 
at 100 µM, where viability of oligodendroglial cells was 
reduced by 7.6 and 13.2 %, respectively (Fig. 5c, d). Fur-
thermore, none of the used glutamate re eptor agonists 
influenced the inhibitory action of KYNA on OLN-93 cells.
Discussion
The route and function of KP and its metabolites ar  well 
established in neurons but n t in oligo end ocytes. Despite 
the demonstrated lack of expression of ndoleam ne 
2,3-dioxygenase (IDO-1) and tryptophan 2,3-dioxygenase 
(TDO-2) in primary human oligodendrocytes [5], the details 
of kynurenines activity within lig dendroglial cells is still
being explored. Recently, Dabrowski and colleagues dem-
onstrated morphologically damage and loss of myelin sheets 
after a 5–7 d ys subdural infusion of high o cen rations 
Fig. 4 Effect of glutamate receptor antagonists on KYNA activity in 
OLN-93 cells in vitro. OLN-93 cells were incubated for 24 h with ind-
cated concentrations of KYNA, CPP, MK-801 and GYKI 52466 alone 
or in combination: KYNA 500 µM + glutamate receptor antagonist (in 
 medium with reduced to 2 % FBS) and viabil ty was measured by 
MTT test. Th  values were means ± SD; n=  6. *At least p < 0.05 vs. 
Control; #at least p< 0.05 (one-way ANOVA test, post test: Tukey)
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of several proteins engaged in the regulation of cellular 
proliferation and cell cycle was explored. ERK1/2 and 
Akt kinases are key regulatory proteins of basic cell 
functions i.e. proliferation, growth and differentiation or 
apoptosis. Phosphorylation of Thr202/Tyr204 and Ser473 
sites is necessary for the activation of ERK1/2 and Akt 
kinases, respectively [14, 15]. I  can be concluded that 
KYNA did not act through the ERK1/2 and Akt regulated 
signaling pathways, since incubation of cells with KYNA 
did not significantly influence the phosphorylation level 
of ERK1/2 and Akt kinases. Furthermore, no meaningful 
changes in expression of cell cycle regulatory proteins 
[16] were observed i.e. cyclin D1, CDK4, CDK6 as well 
as cell cycle inhibitor, p21 protein. This may be consis-
tent with the observations of no influence of KYNA on 
OLN-93 cells proliferation and growth shown in this 
study.
viability/metabolic activity of oligodendrocytes rown a 
medium with a reduced serum concent . This is consis-
tent with the results of Dabrowski et al. [4] demonst ating
damage and loss of myelin sheets n the spina  cord of rats 
after intrathecal KYNA infusion with a simultaneous lack of 
oligodendrocytes injury [4]. Apparently KYNA reduces the 
ability of oligodendrocytes to maintain the myelin sheaths 
due to the reduction in a metabolic activi y that still needs to 
be characterized. Present re ults are unlike our earlier obser-
vations concerning antiprol ferative a tivity of KYNA in a 
broad spectrum of human cancer cell lines i.e. T98G glioma 
(IC50 value of 1.3 mM), HT-29 colon adeno arcinoma (IC50 
value of 0.9mM) and Caki-2 renal carcinoma (IC50 value 
of 0.04 mM) [10–12] as well as normal rabbit s noviocytes 
HIG-82 in vitro (IC50 value of 5.9 mM) [13].
In the attempt to elucidate molecular mechanisms of 
KYNA-related reduction of cell viability, the expression 
Fig. 5 Effect of glutamate receptor agonists on KYNA activity in 
OLN-93 cells in vitro. OLN-93 cells were incubated for 24 h with ind-
cated concentrations of KYNA, glutamate, NMDA, AMPA and ATPA 
alone or in combination: KYNA 500 µM + glutamate receptor agonist 
(in a medium with reduced to 2 % FBS) and viability was measured 
by MTT tes . The values were means ± SD; n =  6. *At least p < 0.05 
vs. Control; #at least p < 0.05 (one-way ANOVA test, post test: Tukey)
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the expression of several subunits of NMDA receptor i.e. 
NR1, NR2A and NR2B, which may suggest no functional 
activity of NMDA receptors [22] and may explain no or 
marginal effect of several glutamate receptor antagonists 
and agonists on oligodendrocytes in our study. However, 
previous study characterizing KYNA synthesis in OLN-93 
cells showed that KYNA production had been altered due 
to glutamate and AMPA treatment, suggesting their interac-
tion with adequate receptors. Similarly to our observations, 
no influence of NMDA had been shown [8]. Furthermore, 
a research performed on OLN-93 cells indicated protective 
effect of NMDA antagonist MK-801 and AMPA antagonist 
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-
7-sulfonamide (NBQX) on OLN-93 cells during oxygen-
glucose deprivation/reperfusion [23] implying functional 
activity of both NMDA and AMPA receptors.
Apart from action on glutamate receptors KYNA is 
known as α7 nicotinic acetylcholine (α7nACh) receptor 
antagonist [24] and an agonist of G-protein receptor GPR35 
[25]. Its action on aryl hydrocarbon receptor (AhR) is dis-
putable due to conflicting reports [26, 27]. Moreover, it has 
been reported that KYNA reduced respiratory parameters 
in isolated rat heart mitochondria [28]. Further studies are 
needed to fully elucidate the mechanism by which KYNA 
affects metabolic activity of oligodendrocytes.
In summary, in an in vitro study we showed that KYNA 
at high levels reduces the viability of oligodendrocytes by 
mechanisms distinct from that of mediated by glutamatergic 
receptors. Our results support the recent observation that 
prolonged subdural administration of high concentrations of 
KYNA in rats produced damage and loss of myelin sheaths 
with no concurrent necrosis of oligodendrocytes.
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